Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Cannabis Stock News: Emerald Health Therapeutics, Inc. (CSE: EMH) Restates Q1 Financial Statements to Meet PCAOB Standard


Vancouver, British Columbia - August 12, 2022 (Newsfile Corp.) ( Newswire) Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announces that it has identified matters which require the Company to make restatements (the "Restatements") in respect of its interim consolidated financial statements for the three months ended March 31, 2022 and 2021 (the "Restated Q1 Financial Statements") and related management discussion and analysis (the "Restated MD&A") relating to (a) cash and cash equivalents (b) revenue from sale of goods and (c) impairment of assets.

The Restatements were identified during a review conducted by MNP LLP ("MNP"), the Company's auditor, in accordance with the standards established by the Public Company Accounting Oversight Board (United States) ("PCAOB") to satisfy the requirements for inclusion of the Company's previously filed financial statements and management's discussion and analysis into the Skye Bioscience, Inc. ("Skye") proxy statement in Form 14A in connection with the previously announced arrangement involving the Company and Skye.

Readers of the Restated Q1 Financial Statements and Restated MD&A should note that the Restatements do not materially change the Company's overall cash position, and do not impact the value of the Company's assets.

A summary of the material Restatements is described below:

  1. certain cash payments had not previously been recognized and as a result, the Restatements include adjustments to reflect the proper application of cash payments received, decreasing the Company's cash balance as of March 31, 2022 by $111,000;
  2. previously unrecognized commission revenue was identified and pass-through sales were noted as not eliminated; as such, the Restatements include adjustments to reflect the proper elimination of pass-through sales and recognition of commission revenue, resulting in a decrease of $167,000 to accounts receivable in the unaudited condensed interim consolidated statement of cash flows for the three months ended March 31, 2022; and
  3. previously unidentified indicators of impairment for biological assets were noted and accordingly, the Restatements include adjustments to reflect the Company's assessment of impairment expense, resulting in a restatement of the balances of inventory write-down and changes in inventory and biological assets in the unaudited condensed interim consolidated statement of cash flows for the three months ended March 31, 2022 to reflect net adjustments of $771,000 and a decrease of $488,000, respectively.

Further details of such matters together with a discussion of various other non-material restatements and adjustments can be found in Note 3 to the Restated Financial Statements and in the Restated M&A, both of which are available under the Company's profile on SEDAR at

Please visit for more information or contact:

Moe Jiwan, Chief Operating Officer
1(800) 757 3536 Ext. #5

Emerald Investor Relations
(800) 757 3536 Ext. #5

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:

Follow Us on StockTwits

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories for Cannabis stocks and Psychedelic Stocks

Buy a cannabis guest post on


Sign up for free stock news alerts at